Assembly Biosciences, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Assembly Biosciences, Inc. (ASMB) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of -$4.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-25.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2021-02-25
- Assembly Biosciences, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2019-12-31 was $0.00.
- Assembly Biosciences, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2019-09-30 was $0.00.
- Assembly Biosciences, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2019-06-30 was $0.00.
- Assembly Biosciences, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2019-03-31 was -$4.00K.
- Assembly Biosciences, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2019 was -$4.00K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | -$4.00K 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | -$4.00K 10-Q · filed 2020-11-05 | $4.00K 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$4.00K 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | -$4.00K 10-Q · filed 2020-05-08 | $4.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |